CVS Posts $1.68 Q3 EPS as Break-Up Talk Swirls
CVS sits 32% above its 52-week low of $69.51 on elevated volume (2.4× avg).
Summary
CVS reported third-quarter EPS of $1.68, the first hard number from its latest quarter, alongside adjusted EPS of $2.09. The print lands a day after Reuters reported the company is discussing a spin-off of its retail pharmacy division, so the results will be read against that break-up debate. Q2 set a high bar: net income of $2.995 billion, nearly triple the prior year, on a sharp rebound in Health Care Benefits. Segment detail now fills out the quarter: Health Services revenue was $53.96 billion, Healthcare Benefits revenue was $36.85 billion, up 2.4%, and Pharmacy & Consumer Wellness revenue fell 2.0%, with front store same-store sales down 0.6%. Watch the full release and call for 2027 Medicare Advantage commentary, following the October shift toward HMOs and reduced PPO offerings.
At the time of this announcement, CVS was trading at $91.84 on NYSE in the Trade & Services sector, with a market capitalization of approximately $116.9B. The 52-week trading range was $69.51 to $110.68. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.